Physicians and scientists of the Department of Immunology actively participate in the world-wide fight against COVID-19. We work together with top international partners to identify genetic factors predisposing otherwise healthy humans to severe course of the disease (for example as part of the consortium https://www.covidhge.com/), with biotech companies to map the development of immune response to the virus (e.g. as part of the initiative https://www.exbio.cz/about-exbio/covid-19) and received funding support as part of the Modern therapies program from the University Hospital in Motol for the project "Innate immune response to SARS-CoV-2 infection".
The manuscript "Allergy to egg in the cohort of 80 Czech infants with food allergy and the natural history of egg allergy" (http://www.tigis.cz/images/stories/Alergie/2019/2_2019/kopelentova_2_19.pdf) by MUDr. Eliška Kopelentová and the manuscript "First thymic transplant in the Czech Republic as a novel therapeutic option for patients with complete DiGeorge syndrome" (http://www.tigis.cz/images/stories/Alergie/2019/Alergie_4_2019/Alergie4_2019_klocperk.pdf) by MUDr. Adam Klocperk, Ph.D. received the award for best works published in the peer-reviewed journal "Alergie" (http://www.tigis.cz/alergie) during the year 2019. Congratulations!
In collaboration with our colleagues from the Department of Pediatrics we published our manuscript "Changes in innate and adaptive immunity over the first year after the onset of type 1 diabetes" in the international peer-reviewed journal Acta Diabetologica (impact factor 2,99). This work described the development of the immune system in children during the first year after onset of autoimmune diabetes mellitus (T1D) and analyses the relationsthips between immune parameters and course of the disease. This manuscript resulted from the Modern therapy funding program of the University Hospital in Motol. More information about the paper can be found at https://www.ncbi.nlm.nih.gov/pubmed/31570993
EN Doc. Jitka Fučíková převzala cenu Milana Pospíšila a Mario Campy za článek v časopise Cancer Immunology and Immunotherapy: Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/Pca in patients with rising PSA after primary prostactetomy or salvage radiotherapy for the treatment of prostate cancer.